As per Intent Market Research, the Companion Animal Arthritis Market was valued at USD 1.7 Billion in 2024-e and will surpass USD 3.2 Billion by 2030; growing at a CAGR of 9.8% during 2025-2030.
The companion animal arthritis market is witnessing significant growth due to the rising prevalence of arthritis among pets, particularly in aging dogs, cats, and horses. As pets live longer and face joint-related health issues, the demand for effective arthritis treatments is expanding. This market encompasses a wide array of treatment options, from non-steroidal anti-inflammatory drugs (NSAIDs) to disease-modifying osteoarthritis drugs (DMOADs), and even surgical interventions. Additionally, with increasing awareness about pet health and the importance of pain management, the market is also seeing a rise in nutraceuticals and physical therapy options to address arthritis symptoms.
NSAIDs Segment Is Largest Owing to Their Effectiveness and Widespread Use
Among the various product types, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) hold the largest share of the companion animal arthritis market. NSAIDs are commonly prescribed for arthritis in companion animals due to their ability to reduce inflammation, alleviate pain, and improve joint mobility. Their effectiveness in managing osteoarthritis symptoms in pets has made them the go-to treatment for veterinary professionals. Popular NSAIDs such as carprofen, meloxicam, and firocoxib are specifically formulated for animals to ensure safety while providing therapeutic benefits. The demand for NSAIDs continues to grow as pet owners seek fast-acting, reliable treatments for their pets' arthritis.
Veterinary Hospitals and Clinics Dominate the End-User Industry
In the end-user industry, veterinary hospitals and clinics account for the largest share of the companion animal arthritis market. These establishments are the primary points of contact for pet owners seeking professional diagnosis and treatment for arthritis. With an increasing number of pets being treated for joint conditions, veterinary hospitals and clinics are witnessing steady growth in demand for arthritis medications and treatments. The presence of highly trained veterinarians and advanced diagnostic tools in these institutions further accelerates the adoption of specialized arthritis care, thereby driving the market for NSAIDs and other therapeutic solutions.
Pharmacological Treatment Segment Sees Strong Growth Due to Advancements in Drug Therapy
In the treatment type segment, pharmacological treatments are experiencing rapid growth. This segment encompasses a wide range of drugs, including NSAIDs, steroids, and disease-modifying osteoarthritis drugs (DMOADs), all of which are crucial in managing arthritis symptoms in pets. With advancements in drug formulations and an increased understanding of arthritis pathophysiology, pharmacological treatments have become more effective and tailored to individual animal needs. This has contributed to an increase in the adoption of these treatments, particularly among pet owners seeking to improve their pets' quality of life without resorting to surgical procedures.
Dogs Segment Is Largest Due to Their Higher Prevalence of Arthritis
The largest animal type segment in the companion animal arthritis market is dogs. As one of the most common pets worldwide, dogs are highly susceptible to arthritis, particularly as they age. The rising number of senior dogs and those with high activity levels has led to a surge in arthritis diagnoses. Additionally, certain dog breeds, such as larger breeds, are more prone to joint issues, further driving the demand for arthritis treatments. Veterinary professionals frequently recommend a combination of NSAIDs, supplements, and physical therapy to manage joint pain and inflammation in dogs, solidifying their position as the largest market segment.
Oral Route of Administration Is Widely Preferred for Ease of Use
Among the different routes of administration, oral treatments dominate the companion animal arthritis market. Oral administration is the most convenient and commonly used method for delivering arthritis medications to pets. NSAIDs, disease-modifying drugs, and supplements are frequently formulated in oral forms, making them easier for pet owners to administer at home. The ease of use, coupled with the availability of flavored tablets and chews designed specifically for pets, has led to high adoption rates for oral treatments. This method also ensures consistent dosing and better compliance with the prescribed treatment regimen.
North America Leads the Companion Animal Arthritis Market in Terms of Revenue
In terms of geographic region, North America holds the largest share of the companion animal arthritis market. The high adoption rate of pets, coupled with increasing awareness of arthritis in animals, has contributed to the growth of the market in this region. The presence of key players in the veterinary pharmaceutical industry and a well-established network of veterinary hospitals and clinics further supports the market's expansion. Additionally, pet owners in North America are increasingly willing to invest in advanced treatments and therapies for their pets, driving demand for arthritis-related products and services.
Leading Companies and Competitive Landscape
Key players in the companion animal arthritis market include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, and Vetoquinol. These companies offer a range of products, including NSAIDs, disease-modifying drugs, and joint supplements, and are actively involved in the development of new treatment options. The competitive landscape is characterized by a focus on innovation, with companies investing in research and development to create more effective and safer arthritis treatments. Additionally, strategic partnerships, acquisitions, and mergers are common as companies seek to expand their portfolios and reach more consumers in the growing companion animal arthritis market.
Recent Developments:
- Zoetis Inc. has launched a new injectable treatment for osteoarthritis in dogs, providing relief for joint pain and improving mobility.
- Boehringer Ingelheim announced the successful completion of a Phase 3 clinical trial for its new disease-modifying osteoarthritis drug for cats.
- Elanco Animal Health introduced a new line of joint supplements formulated to reduce inflammation and support cartilage health in companion animals.
- Merck Animal Health has partnered with a biotechnology company to explore regenerative medicine as a potential treatment for arthritis in pets.
- Nestlé Purina Petcare has acquired a startup specializing in innovative joint health supplements for pets, expanding its portfolio in the companion animal arthritis market.
List of Leading Companies:
- Zoetis Inc.
- Elanco Animal Health
- Boehringer Ingelheim International GmbH
- Merck Animal Health
- Vetoquinol S.A.
- Nestlé Purina Petcare
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Bayer AG
- Virbac
- Antech Diagnostics
- Animalcare Group
- KindredBio
- Hill's Pet Nutrition (Colgate-Palmolive)
- Medtronic PLC
Report Scope:
|
Report Features |
Description |
|
Market Size (2024-e) |
USD 1.7 Billion |
|
Forecasted Value (2030) |
USD 3.2 Billion |
|
CAGR (2025 – 2030) |
9.8% |
|
Base Year for Estimation |
2024-e |
|
Historic Year |
2023 |
|
Forecast Period |
2025 – 2030 |
|
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
|
Segments Covered |
Companion Animal Arthritis Market By Product Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease Modifying Osteoarthritis Drugs (DMOADs), Steroids, Hyaluronic Acid Injections), By End-User Industry (Veterinary Hospitals and Clinics, Pet Care Providers, Research Institutions), By Treatment Type (Pharmacological Treatment, Surgical Treatment, Nutraceuticals and Supplements, Physical Therapy and Rehabilitation), By Animal Type (Dogs, Cats, Horses), By Route of Administration (Oral, Injectable, Topical) |
|
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
|
Major Companies |
Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim International GmbH, Merck Animal Health, Vetoquinol S.A., Nestlé Purina Petcare, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Bayer AG, Virbac, Antech Diagnostics, Animalcare Group, KindredBio, Hill's Pet Nutrition (Colgate-Palmolive), Medtronic PLC |
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
|
1. Introduction |
|
1.1. Market Definition |
|
1.2. Scope of the Study |
|
1.3. Research Assumptions |
|
1.4. Study Limitations |
|
2. Research Methodology |
|
2.1. Research Approach |
|
2.1.1. Top-Down Method |
|
2.1.2. Bottom-Up Method |
|
2.1.3. Factor Impact Analysis |
|
2.2. Insights & Data Collection Process |
|
2.2.1. Secondary Research |
|
2.2.2. Primary Research |
|
2.3. Data Mining Process |
|
2.3.1. Data Analysis |
|
2.3.2. Data Validation and Revalidation |
|
2.3.3. Data Triangulation |
|
3. Executive Summary |
|
3.1. Major Markets & Segments |
|
3.2. Highest Growing Regions and Respective Countries |
|
3.3. Impact of Growth Drivers & Inhibitors |
|
3.4. Regulatory Overview by Country |
|
4. Companion Animal Arthritis Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
4.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) |
|
4.2. Disease Modifying Osteoarthritis Drugs (DMOADs) |
|
4.3. Steroids |
|
4.4. Hyaluronic Acid Injections |
|
4.5. Other Product Types |
|
5. Companion Animal Arthritis Market, by End-User Industry (Market Size & Forecast: USD Million, 2023 – 2030) |
|
5.1. Veterinary Hospitals and Clinics |
|
5.2. Pet Care Providers |
|
5.3. Research Institutions |
|
6. Companion Animal Arthritis Market, by Treatment Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
6.1. Pharmacological Treatment |
|
6.2. Surgical Treatment |
|
6.3. Nutraceuticals and Supplements |
|
6.4. Physical Therapy and Rehabilitation |
|
7. Companion Animal Arthritis Market, by Animal Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
7.1. Dogs |
|
7.2. Cats |
|
7.3. Horses |
|
7.4. Other Companion Animals |
|
8. Companion Animal Arthritis Market, by Route of Administration (Market Size & Forecast: USD Million, 2023 – 2030) |
|
8.1. Oral |
|
8.2. Injectable |
|
8.3. Topical |
|
9. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
|
9.1. Regional Overview |
|
9.2. North America |
|
9.2.1. Regional Trends & Growth Drivers |
|
9.2.2. Barriers & Challenges |
|
9.2.3. Opportunities |
|
9.2.4. Factor Impact Analysis |
|
9.2.5. Technology Trends |
|
9.2.6. North America Companion Animal Arthritis Market, by Product Type |
|
9.2.7. North America Companion Animal Arthritis Market, by End-User Industry |
|
9.2.8. North America Companion Animal Arthritis Market, by Treatment Type |
|
9.2.9. North America Companion Animal Arthritis Market, by Animal Type |
|
9.2.10. North America Companion Animal Arthritis Market, by Route of Administration |
|
9.2.11. By Country |
|
9.2.11.1. US |
|
9.2.11.1.1. US Companion Animal Arthritis Market, by Product Type |
|
9.2.11.1.2. US Companion Animal Arthritis Market, by End-User Industry |
|
9.2.11.1.3. US Companion Animal Arthritis Market, by Treatment Type |
|
9.2.11.1.4. US Companion Animal Arthritis Market, by Animal Type |
|
9.2.11.1.5. US Companion Animal Arthritis Market, by Route of Administration |
|
9.2.11.2. Canada |
|
9.2.11.3. Mexico |
|
*Similar segmentation will be provided for each region and country |
|
9.3. Europe |
|
9.4. Asia-Pacific |
|
9.5. Latin America |
|
9.6. Middle East & Africa |
|
10. Competitive Landscape |
|
10.1. Overview of the Key Players |
|
10.2. Competitive Ecosystem |
|
10.2.1. Level of Fragmentation |
|
10.2.2. Market Consolidation |
|
10.2.3. Product Innovation |
|
10.3. Company Share Analysis |
|
10.4. Company Benchmarking Matrix |
|
10.4.1. Strategic Overview |
|
10.4.2. Product Innovations |
|
10.5. Start-up Ecosystem |
|
10.6. Strategic Competitive Insights/ Customer Imperatives |
|
10.7. ESG Matrix/ Sustainability Matrix |
|
10.8. Manufacturing Network |
|
10.8.1. Locations |
|
10.8.2. Supply Chain and Logistics |
|
10.8.3. Product Flexibility/Customization |
|
10.8.4. Digital Transformation and Connectivity |
|
10.8.5. Environmental and Regulatory Compliance |
|
10.9. Technology Readiness Level Matrix |
|
10.10. Technology Maturity Curve |
|
10.11. Buying Criteria |
|
11. Company Profiles |
|
11.1. Zoetis Inc. |
|
11.1.1. Company Overview |
|
11.1.2. Company Financials |
|
11.1.3. Product/Service Portfolio |
|
11.1.4. Recent Developments |
|
11.1.5. IMR Analysis |
|
*Similar information will be provided for other companies |
|
11.2. Elanco Animal Health |
|
11.3. Boehringer Ingelheim International GmbH |
|
11.4. Merck Animal Health |
|
11.5. Vetoquinol S.A. |
|
11.6. Nestlé Purina Petcare |
|
11.7. Ceva Santé Animale |
|
11.8. Dechra Pharmaceuticals PLC |
|
11.9. Bayer AG |
|
11.10. Virbac |
|
11.11. Antech Diagnostics |
|
11.12. Animalcare Group |
|
11.13. KindredBio |
|
11.14. Hill's Pet Nutrition (Colgate-Palmolive) |
|
11.15. Medtronic PLC |
|
12. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Companion Animal Arthritis Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Companion Animal Arthritis Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
.jpg)
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Companion Animal Arthritis Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
.jpg)
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA